Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy.
Biomed Pharmacother
; 53(2): 90-2, 1999 Mar.
Article
in En
| MEDLINE
| ID: mdl-10337463
ABSTRACT
HAART (highly active antiretroviral therapy) suppresses but does not eradicate HIV-1 infection. However, since the antiretroviral agents used in HAART may also be toxic in the long-term, immunotherapies which correct HIV-1 immunosuppression or the cytokine dysregulation associated with it may be beneficial. In this respect, a double blind multicentric placebo-controlled phase II/III anti-IFN alpha vaccine trial has been carried out on 242 HIV-1 patients, the majority of whom were undergoing HAART treatment. In vaccinated patients (vaccinees) who responded to immunization by increased levels of IFN alpha Abs (whether under HAART or not) when compared to placebo or non-responder vaccinees, a strong correlation was found between an increased IFN alpha neutralizing capacity and the reduction of clinical manifestations.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Autoantibodies
/
Vaccines
/
HIV Infections
/
Immunization
/
Interferon-alpha
/
Anti-HIV Agents
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Biomed Pharmacother
Year:
1999
Document type:
Article
Affiliation country:
Francia